
Immunology and Genetics Journal is the official journal of the Research Center For Immunodeficiencies, Tehran University of Medical Sciences. The journal is a Quarterly peer-reviewed, Open Access journal, publishing high quality scientific (basic and translational) and clinical-epidemiological papers on a wide range of pediatric and adult genetics and immunological topics, including Clinical Genetics, Clinical Immunology, Infection and Immunity, Autoimmunity, Immunobiology, Immunogenetics, Immunohematology, Immunopathology, Transplantation, and Cancer immunology.
This journal, which is supported by Universal Scientific Education and Research Network, publishes original articles, review articles, short communications, letters to the editors, clinical trials, systematic review and meta-analysis, and case reports. The quality and originality of the research are the most important criteria for acceptance. Immunology and Genetics Journal attempts to ensure a quick publication of all manuscripts while preserving the highest quality of contents.
All submitted manuscripts are checked for similarity through a trustworthy software named iThenticate to be assured about its originality.
- Country of Publication: Iran
- Owner: Tehran University of Medical Sciences
- Publisher: Tehran University of Medical Sciences
- Format: Electronic Only
- E-ISSN: 2645-4831
- Acceptance Rate: 30%
- Frequency: Quarterly
- Language: English
- Scope: High quality scientific (basic and translational) and clinical-epidemiological papers on a wide range of pediatrics and adult immunological and genetical disorders including topics such as Clinical immunology, Infection immunology, Immunobiology, Immunogenetics, Immunohematology, Immunopathology, Transplantation immunology, Tumor immunology.
- Article Processing Charges: Free of charge
- Type of Journal: Scientific - research
- Open Access: All papers are freely available
- Peer Review Policy: Double Blind Peer Review
- Review Time: 2-4 Months
- Contact E-mail: igj.journal@gmail.com
Articles in Press
Current Issue
Original Article
-
Background: Monkeypox virus (MPXV) is a zoonotic pathogen that influences humans as well as animalsposing a significant public health concern due to its emergence and circulation. The structural dynamics and features of several MPXV proteins, including M1R, have not been completely studied.
Methods: This experiment focuses on the prediction and analysis of the secondary and tertiary constructs for the M1R protein. Briefly, its amino acid sequence was collected from the UniProt database. A wide range of in silico approaches were employed, including ProtParam, SOPMA, PSIPRED, CD Search, GalaxyTMB, Robetta, I-TASSER, and GROMACS, in order to explore the physicochemical properties, structural features, and functional insights of the M1R protein. The tertiary structure models were evaluated to detect the most reliable solution, which was then used for Immunoinformatics analyses such as MHC I/II and B-cell epitope prediction using the IEDB and Ellipro tools, respectively. Epitopes from the M1R protein were evaluated based on antigenicity, affinity of binding, along solubility. Furthermore, active sites were forecast by the CASTp v3.0 tool.
Results: Physicochemical calculations indicate that M1R had favorable thermostability and hydrophilic features. Structural analyses suggested that M1R is a lipid membrane protein component of DNA viruses, suggesting it as a robust antigenic target. Immunogenicity analyses indicated it as a potentially suitable target for immunogenic protein design. As well, molecular dynamics simulations (MDS) were carried out for 100-ns using an all-atom forcefield. Analysis of various molecular dynamics parameters of M1R throughout the MDS trajectory, including RMSD, RMSF, radius of gyration (Rg), and solvent accessible surface area (SASA), indicated good stability of the M1R and unveiled important molecular dynamics characteristics such as the flexibility of certain protein regions.
Conclusion: Multiple epitopes were detected in our experiment, with 12 B-cell epitopes identified using the Robetta model and 6 B-cell epitopes predicted by the Galaxy model, alongside 3 MHC-I and 3 MHC-II epitopes, which scored favorably. Results of the present computational analysis provide clues to unleash the potential of M1R as an immunotherapy target for the development of antiviral solutions against MPXV in the future.
Case Report
-
The peculiarity of the chromosomally integrated form of human herpesvirus type 6 (ciHHV-6) is its wide distribution (up to 1% of the population), the possibility of transmission by inheritance, the problem of diagnosis, including issues of differential diagnosis with the acute form of HHV-6 infection, which, in turn, makes it difficult to resolve the problem of the therapy necessity. In addition, activation of ciHHV-6 is possible sometimes with acute infection clinical symptoms and the need for antiviral therapy, especially in patients after bone marrow transplantation and chemotherapy. We report a 10-years-old girl after chiasmal-sellar germinoma surgery and subsequent chemotherapy with ciHHV-6B. The child was treated with ganciclovir. This did not significantly influence the reduction of the viral load HHV-6B DNA in serum and cerebrospinal fluid. No adverse effects of antiviral treatment were registered. It’s important to exclude ciHHV-6 before the diagnosis of HHV-6 active disease is made, as this screening may prevent the unnecessary use of antivirals.